Thus, in a population men with hypogonadism and PSA concentrations less than 3 ng/mL who were evaluated carefully to exclude those at increased prostate cancer risk, TRT was associated with low risk of adverse prostate events, including cancer. This evidence concerns the gene KLK3 and prostate carcinoma.